Enliven Therapeutics ELVN Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -27%+5.1pp | -32%— | —— | —— | |
| Return on assets | -25.9%+3.9pp | -29.8%+10.5pp | -40.3%+2.3pp | -42.6%+13.1pp | |
| Liquidity | |||||
| Current ratio | 28.7×+8.7× | 20×+9.7× | 10.3×+2.3× | 8×-4.9× | |
| Quick ratio | 28.7×+8.7× | 20×+9.7× | 10.3×+2.3× | 8×-4.9× | |
| Cash ratio | 6×-1.8× | 7.8×+3.9× | 3.9×-3.9× | 7.8×+1.1× | |
| Leverage | |||||
| Debt-to-equity | 0×— | —— | 0×— | —— | |
| Debt-to-assets | 0×— | —— | 0×— | —— | |
| Interest coverage | -7.5×-0.5× | -7×0.0× | -7×+27.4× | -34.4×+186× | |
| Per Share | |||||
| Book value per share | $8.11+23.2% | $6.58-4.9% | $6.92+128% | -$24.59-1,142% | |
| Valuation | |||||
| Market capitalization | $913.95M-16.9% | $1.1B+93.1% | $569.21M+429% | $107.51M+81.8% | |
| Enterprise value | $815.45M— | —— | $469.41M— | —— | |
| Price / book | 2×-1.6× | 3.5×+1.2× | 2.3×— | —— | |
| Free cash flow yield | -7.7%-1.0pp | -6.7%+4.1pp | -10.8%+19.6pp | -30.4%+48.7pp | |
| Earnings yield | -11.3%-3.2pp | -8.1%+4.5pp | -12.6%+22.5pp | -35%+51.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Enliven Therapeutics's ratios come from?
- Every ratio is computed from Enliven Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.